Celgene posts higher quarterly profit

Oct 26 (Reuters) - Celgene Corp said its third-quarter profit was nearly six times higher than a year ago, helped by a rise in sales of its multiple myeloma drug Revlimid as well as lower costs.

The U.S. biotechnology company's net income rose to $988 million, or $1.21 per share, in the quarter ended Sept. 30, from $171 million, or 21 cents per share, a year earlier.

Revenue rose to $3.29 billion from $2.98 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio D'Souza)